temozolomide has been researched along with dasatinib in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (42.86) | 29.6817 |
2010's | 3 (42.86) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
Authors | Studies |
---|---|
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Clynes, M; Crown, J; Eustace, AJ; O'Donovan, N | 1 |
de Groot, J; LaFortune, T; Milano, V; Piao, Y | 1 |
Cubitt, CL; Daud, AI; Homsi, J; Jove, R; Messina, JL; Munster, PN; Sullivan, DM; Yu, H; Zhang, S | 1 |
Campian, JL; Chang, X; Fergus, S; Hallahan, D; Huang, J; Hui, C; Lin, AJ; Mullen, D; Rao, YJ; Rudra, S; Samson, P; Thotala, D; Tsien, C; Yang, D | 1 |
Corbacioglu, S; Heise, T; Leister, J; Matthes, M; Penkivech, G; Sommer, G; Waetzig, R | 1 |
1 review(s) available for temozolomide and dasatinib
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
6 other study(ies) available for temozolomide and dasatinib
Article | Year |
---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Dasatinib; Drug Screening Assays, Antitumor; Drug Synergism; Focal Adhesion Protein-Tyrosine Kinases; Humans; Melanoma; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins pp60(c-src); Pyridines; Pyrimidines; Receptor, EphA2; Sorafenib; Temozolomide; Thiazoles | 2008 |
Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma.
Topics: Apoptosis; Autophagy; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Dasatinib; Drug Screening Assays, Antitumor; Drug Synergism; G1 Phase; Glioma; Humans; PTEN Phosphohydrolase; Pyrimidines; Temozolomide; Thiazoles | 2009 |
Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.
Topics: Aniline Compounds; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cisplatin; Dacarbazine; Dasatinib; Drug Synergism; Enzyme Activation; Humans; Inhibitory Concentration 50; Melanoma; Nitriles; Paclitaxel; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Skin Neoplasms; src-Family Kinases; Temozolomide; Thiazoles | 2009 |
Effect of Radiation Treatment Volume Reduction on Lymphopenia in Patients Receiving Chemoradiotherapy for Glioblastoma.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bevacizumab; Carmustine; Chemoradiotherapy; Dasatinib; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Lymphocyte Count; Lymphopenia; Male; Middle Aged; Photons; Progression-Free Survival; Propensity Score; Quinazolines; Radiotherapy Dosage; Radiotherapy, Conformal; Snake Venoms; Supratentorial Neoplasms; Temozolomide; Young Adult | 2018 |
Comparing mTOR inhibitor Rapamycin with Torin-2 within the RIST molecular-targeted regimen in neuroblastoma cells.
Topics: Administration, Metronomic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Indoles; Inhibitory Concentration 50; Irinotecan; Naphthyridines; Neuroblastoma; Purines; Pyrimidines; Signal Transduction; Sirolimus; Temozolomide; Thiourea; TOR Serine-Threonine Kinases | 2021 |